The FDA granted Schrodinger orphan status for its treatment of mantle cell lymphoma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SDGR:
- Schrodinger price target lowered to $67 from $78 at BMO Capital
- Schrodinger (NASDAQ:SDGR) Tanks after Q2 Numbers Disappoint
- Schrodinger down 15% at $42.90 after Q2 results, updated guidance
- Schrodinger raises FY23 software revenue growth view to 15%-18% from 13%-17%
- Schrodinger reports Q2 EPS (79c), consensus (41c)